Transgene SA (FR:TNG)
:TNG
Want to see FR:TNG full AI Analyst Report?
TNG Stock Chart & Stats
€0.94
<€0.01(0.40%)
At close: 4:00 PM EST
€0.94
<€0.01(0.40%)
Day’s Range― - ―
52-Week Range€0.73 - €1.50
Previous CloseN/A
Volume15.92K
Average Volume (3M)129.86K
Market Cap
€213.48M
Enterprise Value€115.81M
Total Cash (Recent Filing)€111.86M
Total Debt (Recent Filing)€2.06M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding277,532,530
10 Day Avg. Volume204,663
30 Day Avg. Volume129,863
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)1.14
Price to Sales (P/S)1011.31
P/FCF Ratio-3.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€9.01M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetTransgene's very low debt-to-equity and material equity cushion provide durable financial flexibility over the next several months. Low leverage reduces refinancing and interest burdens, enabling continued R&D spend or partner-funded programs without near-term solvency pressure, supporting program continuity.
Platform R&D And Manufacturing CapabilitiesA diversified R&D platform (therapeutic vaccines, viral vectors, neoantigen and enabling manufacturing) gives Transgene structural advantages: it can advance multiple clinical assets, attract collaborations, and internalize CMC execution. This persistent capability supports program progression and partner interest over months.
Partnering-based Revenue ModelReliance on collaboration, licensing, milestones and grant streams is a durable business model for clinical biotechs. It enables financing of R&D without commercial products, aligns incentives with larger partners, and can deliver non-dilutive or milestone-timed funding that supports development runway over the medium term.
Bears Say
Persistent Cash BurnOperating cash flow remains strongly negative, translating net losses into real cash consumption. Persistent negative OCF and FCF imply the company will need external financing or partner payments to sustain operations, creating ongoing execution and financing risk across the 2–6 month horizon.
Sharp Revenue Collapse In 2025A ~96% decline in reported revenue signals volatile, non-recurring top-line streams and limited internal cash generation. Over the medium term this undermines margin recovery prospects and increases dependence on partners or financing to fund R&D, weakening operational stability and predictability.
Funding Dependence And Dilution RiskAlthough equity is sizable now, historical equity fluctuations highlight reliance on episodic capital raises or partner financing. This structural funding dependence raises dilution risk for shareholders and could constrain strategic optionality if future financing terms are unfavorable across upcoming quarters.
Transgene News
TNG FAQ
What was Transgene SA’s price range in the past 12 months?
Transgene SA lowest stock price was €0.73 and its highest was €1.50 in the past 12 months.
What is Transgene SA’s market cap?
Transgene SA’s market cap is €213.48M.
When is Transgene SA’s upcoming earnings report date?
Transgene SA’s upcoming earnings report date is Sep 24, 2026 which is in 104 days.
How were Transgene SA’s earnings last quarter?
Currently, no data Available
Is Transgene SA overvalued?
According to Wall Street analysts Transgene SA’s price is currently Overvalued.
Does Transgene SA pay dividends?
Transgene SA does not currently pay dividends.
What is Transgene SA’s EPS estimate?
Transgene SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transgene SA have?
Transgene SA has 277,532,530 shares outstanding.
What happened to Transgene SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Transgene SA?
Currently, no hedge funds are holding shares in FR:TNG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Transgene SA
Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―